A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete freund’s adjuvant in patients with resected high-risk melanoma

Jeffrey S. Weber, Flora L. Hua, Lucy Spears, Verna Marty, Catherine Kuniyoshi, Esteban Celis

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are intracellularly processed and delivered to the cell surface in conjunction with HLA molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor challenges. To test whether epitope peptides derived from a human tumor antigen can induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE and emulsified with incomplete Freund’s adjuvant. Eighteen patients with resected stages III and IV melanoma at high risk for relapse were vaccinated subcutaneously with increasing doses of the MAGE-3 vaccine ranging from 100 to 2,000 µg per injection four times, each 4 weeks apart. The purpose of the phase I trial was to assess the toxicity, tolerability, and immune responses to the vaccine. The vaccine was not toxic, with only one case of grade III lethargy, and most patients complaining of grade I or II local pain, swelling, and tenderness at the injection sites. Peripheral blood mononuclear cells (PBMC) were collected from most patients prior to and after vaccination and used for assessment of global levels of immunity prevaccination, and to measure immune responses to the MAGE-3 and PADRE peptides prior to and after vaccination. Significant defects in global immunity shown by anergy to DTH skin testing in 7 of 16 patients and decreased proliferation to PHA (phytohemagglutinin) and CASTA, a protein extract, were observed. Seven of nine patients showed an increased response to PADRE after restimulation in vitro. Five of 14 patients at doses from 100 to 2,000 µg demonstrated an immune response to MAGE-3 by cytolysis of MAGE-3-specific target cells. Release of gamma interferon by T cells from 8 patients at the 100, 1,000, or 2,000 µg dose was measured after vaccination, and only two of eight patients showed an increase indicating augmented antigen-specific immunity. These data suggest that immune resonses can be detected against PADRE and MAGE-3 in vaccinated melanoma patients, albeit with a low frequency of effector cells.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalJournal of Immunotherapy
Volume22
Issue number5
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

HLA-A1 Antigen
Epitopes
Melanoma
Peptides
Vaccines
Immunity
Vaccination
Antigens
Tumor Virus Infections
incomplete Freund's adjuvant
Lethargy
Subunit Vaccines
Injections
Peptide Fragments
Poisons
Phytohemagglutinins
Neoplasm Antigens
Helper-Inducer T-Lymphocytes
Interferon-gamma
Blood Cells

Keywords

  • Adjuvant
  • Epitope
  • HLA-A1
  • Immunotherapy
  • Melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete freund’s adjuvant in patients with resected high-risk melanoma. / Weber, Jeffrey S.; Hua, Flora L.; Spears, Lucy; Marty, Verna; Kuniyoshi, Catherine; Celis, Esteban.

In: Journal of Immunotherapy, Vol. 22, No. 5, 01.01.1999, p. 431-440.

Research output: Contribution to journalArticle

Weber, Jeffrey S. ; Hua, Flora L. ; Spears, Lucy ; Marty, Verna ; Kuniyoshi, Catherine ; Celis, Esteban. / A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete freund’s adjuvant in patients with resected high-risk melanoma. In: Journal of Immunotherapy. 1999 ; Vol. 22, No. 5. pp. 431-440.
@article{b45b6aeb1f794509a669bb6ea2934222,
title = "A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete freund’s adjuvant in patients with resected high-risk melanoma",
abstract = "Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are intracellularly processed and delivered to the cell surface in conjunction with HLA molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor challenges. To test whether epitope peptides derived from a human tumor antigen can induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE and emulsified with incomplete Freund’s adjuvant. Eighteen patients with resected stages III and IV melanoma at high risk for relapse were vaccinated subcutaneously with increasing doses of the MAGE-3 vaccine ranging from 100 to 2,000 µg per injection four times, each 4 weeks apart. The purpose of the phase I trial was to assess the toxicity, tolerability, and immune responses to the vaccine. The vaccine was not toxic, with only one case of grade III lethargy, and most patients complaining of grade I or II local pain, swelling, and tenderness at the injection sites. Peripheral blood mononuclear cells (PBMC) were collected from most patients prior to and after vaccination and used for assessment of global levels of immunity prevaccination, and to measure immune responses to the MAGE-3 and PADRE peptides prior to and after vaccination. Significant defects in global immunity shown by anergy to DTH skin testing in 7 of 16 patients and decreased proliferation to PHA (phytohemagglutinin) and CASTA, a protein extract, were observed. Seven of nine patients showed an increased response to PADRE after restimulation in vitro. Five of 14 patients at doses from 100 to 2,000 µg demonstrated an immune response to MAGE-3 by cytolysis of MAGE-3-specific target cells. Release of gamma interferon by T cells from 8 patients at the 100, 1,000, or 2,000 µg dose was measured after vaccination, and only two of eight patients showed an increase indicating augmented antigen-specific immunity. These data suggest that immune resonses can be detected against PADRE and MAGE-3 in vaccinated melanoma patients, albeit with a low frequency of effector cells.",
keywords = "Adjuvant, Epitope, HLA-A1, Immunotherapy, Melanoma",
author = "Weber, {Jeffrey S.} and Hua, {Flora L.} and Lucy Spears and Verna Marty and Catherine Kuniyoshi and Esteban Celis",
year = "1999",
month = "1",
day = "1",
doi = "10.1097/00002371-199909000-00007",
language = "English (US)",
volume = "22",
pages = "431--440",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete freund’s adjuvant in patients with resected high-risk melanoma

AU - Weber, Jeffrey S.

AU - Hua, Flora L.

AU - Spears, Lucy

AU - Marty, Verna

AU - Kuniyoshi, Catherine

AU - Celis, Esteban

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are intracellularly processed and delivered to the cell surface in conjunction with HLA molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor challenges. To test whether epitope peptides derived from a human tumor antigen can induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE and emulsified with incomplete Freund’s adjuvant. Eighteen patients with resected stages III and IV melanoma at high risk for relapse were vaccinated subcutaneously with increasing doses of the MAGE-3 vaccine ranging from 100 to 2,000 µg per injection four times, each 4 weeks apart. The purpose of the phase I trial was to assess the toxicity, tolerability, and immune responses to the vaccine. The vaccine was not toxic, with only one case of grade III lethargy, and most patients complaining of grade I or II local pain, swelling, and tenderness at the injection sites. Peripheral blood mononuclear cells (PBMC) were collected from most patients prior to and after vaccination and used for assessment of global levels of immunity prevaccination, and to measure immune responses to the MAGE-3 and PADRE peptides prior to and after vaccination. Significant defects in global immunity shown by anergy to DTH skin testing in 7 of 16 patients and decreased proliferation to PHA (phytohemagglutinin) and CASTA, a protein extract, were observed. Seven of nine patients showed an increased response to PADRE after restimulation in vitro. Five of 14 patients at doses from 100 to 2,000 µg demonstrated an immune response to MAGE-3 by cytolysis of MAGE-3-specific target cells. Release of gamma interferon by T cells from 8 patients at the 100, 1,000, or 2,000 µg dose was measured after vaccination, and only two of eight patients showed an increase indicating augmented antigen-specific immunity. These data suggest that immune resonses can be detected against PADRE and MAGE-3 in vaccinated melanoma patients, albeit with a low frequency of effector cells.

AB - Cytolytic and helper T cells recognize small peptide fragments of protein antigens that are intracellularly processed and delivered to the cell surface in conjunction with HLA molecules. In mice, peptide vaccines can protect against lethal virus infections and tumor challenges. To test whether epitope peptides derived from a human tumor antigen can induce immune responses in patients, a vaccine was prepared consisting of an HLA-A1-restricted epitope of the antigen MAGE-3 mixed with a pan-class II epitope peptide PADRE and emulsified with incomplete Freund’s adjuvant. Eighteen patients with resected stages III and IV melanoma at high risk for relapse were vaccinated subcutaneously with increasing doses of the MAGE-3 vaccine ranging from 100 to 2,000 µg per injection four times, each 4 weeks apart. The purpose of the phase I trial was to assess the toxicity, tolerability, and immune responses to the vaccine. The vaccine was not toxic, with only one case of grade III lethargy, and most patients complaining of grade I or II local pain, swelling, and tenderness at the injection sites. Peripheral blood mononuclear cells (PBMC) were collected from most patients prior to and after vaccination and used for assessment of global levels of immunity prevaccination, and to measure immune responses to the MAGE-3 and PADRE peptides prior to and after vaccination. Significant defects in global immunity shown by anergy to DTH skin testing in 7 of 16 patients and decreased proliferation to PHA (phytohemagglutinin) and CASTA, a protein extract, were observed. Seven of nine patients showed an increased response to PADRE after restimulation in vitro. Five of 14 patients at doses from 100 to 2,000 µg demonstrated an immune response to MAGE-3 by cytolysis of MAGE-3-specific target cells. Release of gamma interferon by T cells from 8 patients at the 100, 1,000, or 2,000 µg dose was measured after vaccination, and only two of eight patients showed an increase indicating augmented antigen-specific immunity. These data suggest that immune resonses can be detected against PADRE and MAGE-3 in vaccinated melanoma patients, albeit with a low frequency of effector cells.

KW - Adjuvant

KW - Epitope

KW - HLA-A1

KW - Immunotherapy

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=0032878254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032878254&partnerID=8YFLogxK

U2 - 10.1097/00002371-199909000-00007

DO - 10.1097/00002371-199909000-00007

M3 - Article

VL - 22

SP - 431

EP - 440

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 5

ER -